Healthcare Industry News: HSMN NewsFeed
News Release - September 9, 2011
Mylan Receives Approval for Promethazine Hydrochloride Tablets, USPPITTSBURGH, Sept. 9, 2011 -- (Healthcare Sales & Marketing Network) -- Mylan Inc. (Nasdaq:MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Promethazine Hydrochloride (HCl) Tablets USP, 12.5 mg, 25 mg and 50 mg. Promethazine HCl Tablets are used to relieve the symptoms of certain allergic reactions, such as perennial and seasonal allergic rhinitis.
Promethazine HCl Tablets had U.S. sales of approximately $42 million for the 12 months ending June 30, 2011, according to IMS Health. Mylan is shipping this product immediately.
Currently, Mylan has 161 ANDAs pending FDA approval representing $97.1 billion in annual sales, according to IMS Health. Forty-three of these pending ANDAs are potential first-to-file opportunities, representing $26.9 billion in annual brand sales, for the 12 months ending June 30, 2011, according to IMS Health.
Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com .
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsMylan to Acquire the Global Marketing Rights to a Once-monthly Glatiramer Acetate Product through an Investment and Partnership with Israeli Company Mapi Pharma
Mylan Introduces Symfi(TM) Triple Combo Once-Daily HIV Treatment in the U.S.
Mylan Adds to Growing Oncology Portfolio with Launch of Generic Mutamycin(R) Injection